Welcome to our dedicated page for GENTEX SEC filings (Ticker: GNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gentex Corporation's SEC filings document recurring financial-reporting, governance and capital-allocation disclosures for an operating technology supplier. Recent Form 8-K reports furnish quarterly and annual earnings releases, including net sales, margins, operating income, share repurchases, and separate references to core Gentex results and VOXX contributions after the completed acquisition.
Proxy materials cover board elections, shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filing record frames Gentex's public-company reporting around its digital vision, connected car, dimmable glass, fire protection, medical device and consumer electronics businesses.
Pink Billy reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Billy Pink reported receiving an equity award of 5,626 shares of Common Stock. The award was granted at a stated price of $0.00 per share as a compensation grant. According to the footnote, these shares vest 100% one year from the grant award date. Following this award, Pink directly holds 15,329 shares of Gentex common stock.
DEUR GARTH reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Garth Deur received a grant of 5,626 shares of Common Stock as a compensation award. The award was reported at a price of $0.00 per share, indicating it is not an open-market purchase but a share grant. Following this transaction, his directly held position increased to 20,045 shares of Common Stock. A footnote explains that these granted shares vest 100% one year from the grant award date, meaning he will gain full ownership rights to the entire award after that one-year vesting period.
BROWN LESLIE L reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Leslie L. Brown received a grant of 5,626 shares of Common Stock, which vest 100% one year from the grant date. After this award, Brown directly holds 41,988 shares. This is a compensation-related equity grant rather than an open-market purchase.
Gentex Corp director Brian C. Walker reported an open-market sale of 5,939 shares of Gentex common stock at an average price of $22.9752 per share. After this transaction, he directly owns 24,205 Gentex shares, indicating he retains a meaningful continuing stake in the company.
GENTEX CORP director Joseph B. Anderson Jr. reported an open-market sale of 5,939 shares of Common Stock on May 15, 2026 at an average price of $22.9752 per share. Following this transaction, his directly held Common Stock position reported in this filing is 0 shares.
Gentex Corporation reported higher first-quarter 2026 results, helped by its VOXX acquisition and steady core operations. Net sales rose to $675.4 million from $576.8 million, a 17% increase, with VOXX contributing $88.6 million and core Gentex revenue edging up despite lower global light vehicle production.
Gross margin improved to 33.8%, supported by operational efficiencies and better product mix, partly offset by tariffs and commodity costs. GAAP net income attributable to Gentex increased to $98.5 million from $94.9 million, and diluted EPS rose to $0.46 from $0.42. Non‑GAAP adjusted diluted EPS was $0.48, versus $0.43 a year earlier.
The company recorded a $2.8 million impairment on Vaporsens in‑process R&D and a $2.7 million impairment on a technology investment, along with a $2.2 million increase in credit loss allowances on loans to technology investees. Gentex ended the quarter with $164.8 million in cash and cash equivalents and generated $137.1 million in operating cash flow.
Gentex Corp director Leslie L. Brown reported a combination of option exercises and share sales. On May 5, 2026, Brown sold 10,782 shares of Gentex common stock in an open-market sale at a weighted average price of $22.847 per share.
On the same date, Brown exercised stock options to acquire a total of 14,000 shares of common stock, including 7,000 options at $18.70 and 7,000 options at $15.74 per share. Following these transactions, Brown directly owned 36,362 common shares. The exercised options came from non‑employee director grants originally exercisable in 2016 and 2017 with expirations in 2026 and 2027.
Gentex Corp director Richard O. Schaum exercised stock options and sold shares in a routine portfolio move. He exercised options covering 7,000 shares of Common Stock at $15.74 per share and sold 4,815 Common shares in an open‑market sale at a weighted average price of $23.312.
Following these transactions, Schaum directly owns 81,443 Gentex Common shares. No remaining derivative option position is reported in this filing.